Cantargia: Comments on the Recent Opposition, Deal and CAN10 News - Redeye
Redeye has looked into the opposition against Cantargia's patent EP3293202 earlier this month and finds a common denominator in the recently announced deal for an IL1RAP antibody, which is a potential competitor to CAN10.
ANNONS
Redeye has looked into the opposition against Cantargia's patent EP3293202 earlier this month and finds a common denominator in the recently announced deal for an IL1RAP antibody, which is a potential competitor to CAN10.